What this site is and is not

The editorial position

Doctor Tirzepatide is an independent editorial project that publishes summaries of the peer-reviewed research literature on Tirzepatide.

We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The 'Doctor' in the name is editorial framing — it stakes a position relative to the literature, not a claim about professional services on this site. There are no doctors here. There is a reading desk, a citation list, and a commitment to saying exactly what the studies measured and what they did not.

What we cover and how we do it

This site covers tirzepatide — a dual GIP and GLP-1 receptor agonist that is FDA-approved for type 2 diabetes, obesity, and obstructive sleep apnea. We follow the published clinical trial record: the SURPASS programme in type 2 diabetes, the SURMOUNT programme in obesity, and the expanding body of beyond-glycaemia evidence.

Every quantitative claim on this site cites a numbered source. Every source appears in the references list with its DOI or PubMed URL. Confirmed findings carry a CONFIRMED label. Open questions and evidence gaps carry a GAP label. Safety cautions are clearly marked.

We do not write about drug brands. We use the international nonproprietary name 'tirzepatide' throughout. We do not write dosing recommendations — labeled doses are described as documented in the FDA prescribing information or clinical trial protocols, attributed to those sources, never personalised.

The community-reported effects on the effects page are presented as patient-community signals, clearly labeled 'anecdotal, not clinical evidence.' They are separated from the cited trial record throughout.

Editorial limitations

This site is a reading of the literature as it stood when each page was written. It is not a live clinical reference and does not update in real time. It does not cover compounded formulations of tirzepatide, which raise separate questions about quality, purity, and regulatory status outside the scope of the approved-drug literature.

Nothing on this site constitutes medical advice, clinical guidance, or a treatment recommendation. If you are considering tirzepatide as a treatment, the relevant conversation is with a licensed prescriber who has access to your clinical history.